A new pathway leading to arthritis has been revealed by the discovery that antibodies specific for a ubiquitously expressed antigen are able to transfer a severe arthritic phenotype in mice. This new model will be useful for further analyses of the different pathways involved in rheumatoid arthritis.
It is still unknown why peripheral joints are the primary target in a variety of diseases that affect a large proportion of the human population. For example, in osteoarthritis, cartilaginous weight-bearing joints degenerate or are destroyed by poorly understood inflammatory processes. In a diverse group of diseases that affect joint capsules, such as psoriasis arthritis and ankylosing spondylitis, inflammatory and regenerative responses lead to pathological processes in the insertion areas of tendons, joint deformities and/or fusions. In rheumatoid arthritis, peripheral diarthrodial cartilaginous joints, for example joints in hands and feet, are attacked by an erosive inflammatory process leading to joint destruction and chronic disability. From an evolutionary standpoint, it would seem important to have intact and non-diseased joints but, in reality, these parts of the body seem to be particularly afflicted by disease. Why is this so?
Joints are vulnerable to trauma by their very nature. In particular, today's environment forces us to use our joints in a different way from that which has been genetically selected and this could induce degeneration or deformations of the joints. Also, macrophages are present in joints and these cells function both in a systemic manner to phagocytose circulating infectious pathogens or debris and in a localised manner to clear the joints of scavenged debris derived from cartilage. This defence system could overreact, leading to autoreactivity, or react unsuitably, resulting in the persistence of pathogens. Finally, joints contain cartilage, which is not vascularized or drained by lymphatic vessels. These areas may therefore contain proteins that have not been fully exposed to the immune system and could lead to autoimmune inflammatory destruction of the joints.
All of the above factors influence the various joint diseases, but to different degrees in each case. Rheumatoid arthritis is believed to be caused by a disturbance in the normal interactions between the immune system and the defence system within the joints. This disruption results in the transformation of the macrophages and inflammatory cells in the synovial fluid surrounding the joints to form a so-called pannus tissue that erodes the joints. The likelihood that new inflammatory phenomena or factors will be detected in rheumatoid arthritis is high because most inflammatory pathways seem to operate in this disease. Thus, although rheumatoid arthritis is defined by a number of criteria that mirror a joint-destructive inflammatory process, it is a very heterogeneous disease in terms of phenotype. The genetic heterogeneity of this disease is most likely to be even more pronounced. In other words, there are many different pathways that lead to rheumatoid arthritis. Some of these lead to the same type of pathology, whereas others produce slightly different variants of the syndrome we call rheumatoid arthritis.
This variability is reflected in the described animal models for rheumatoid arthritis. Although no model can accurately reflect every aspect of such a heterogeneous disease, each model may represent different pathogenic aspects of relevance (Table 1) . Mathis, Benoist and coworkers [1] have recently described a new model for rheumatoid arthritis. They first discovered that a T-cell receptor transgene, when bred into mice expressing the major histocompatibility complex (MHC) class II molecule A g7 , led to severe arthritis with high penetrance. The transgenic T cells were specifically activated in response to an unknown, ubiquitously expressed self-peptide in context with the A g7 molecule.
This group has now reported that this disease is caused by antigen-specific immunoglobulin G (IgG) antibodies [2] . Transfer of serum or purified serum IgG antibodies from the T-cell receptor transgenic mice into wild-type mice resulted in the onset of arthritis as early as 24 hours after transfer. The IgG-induced disease had some similar characteristics to the spontaneously occurring arthritis in the T-cell receptor transgenic mice, but differed in that it was transient and the healing process did not result in the deformation of joints. In contrast, in the T-cell receptor transgenic mouse, which has sustained levels of arthritogenic antibodies, the healing response includes extensive new bone formation leading to remodelling and deformation of the joints that is not typical for rheumatoid arthritis. A more detailed comparison of the IgG-induced model with earlier established models for rheumatoid arthritis points to a number of important similarities and differences.
This IgG-induced disease has several similarities with various rheumatoid arthritis models induced by cartilage proteins, for example collagen-induced arthritis, because the arthritis is dependent on both T and B cells and transient arthritis can be induced with IgG self-reactive antibodies or autoantibodies (reviewed in [3] ). In fact, the kinetics and pathology of the described IgG-mediated arthritis is indistinguishable from anti-type II collagen antibody-mediated arthritis. In addition, unlike rheumatoid arthritis but like collagen-induced arthritis, there is a paucity of lymphocytes in joints. The main difference between IgG-induced disease and collagen-induced arthritis, however, is the apparent lack of cartilage-specific immunity in IgG-induced arthritis. The arthritogenic IgG antibodies recognise an antigen that is ubiquitously expressed and not specific to cartilage. It remains an important possibility that the ubiquitously expressed protein is exposed in the joints as a neo-epitope -that is, it is expressed by traumatised, stressed or apoptotic cells in peripheral joints, and then released to form precipitating immune complexes that trigger the inflammation. A similar mechanism may occur in the classical antigeninduced arthritis model, in which arthritis occurs following the injection of bovine serum albumin into the joints of mice that have previously been immunized with the same foreign protein.
A comparison with other spontaneously occurring arthritis models, such as mice overexpressing tumour necrosis factor α [4] or the spontaneously occurring arthritis in stressed mice [5] reveals several histopathological similarities, such as the extensive remodelling of the joints. In both of these spontaneously occurring models, however, the immune system seems to play no role. Nevertheless, the model in stressed mice is of general importance because it seems to reflect a common pathway in response to trauma or stress that, in most mouse strains, and most likely also in humans, leads to deformation and healing of tendon insertions (enthesopathy). In certain mouse strains, this can be severe and can be mistaken macroscopically for collagen-induced arthritis. Interestingly, a similar form of enthesopathy can be induced in mice given an overdose of vitamin A [6] . Thus, the activation of a ubiquitously expressed protein, such as a hormonal receptor, could also trigger a pathway leading to arthritis.
A comparison of IgG-induced arthritis with various adjuvant-induced arthritis models, such as the pristaneinduced arthritis in rats [7] , is of interest because these models share the lack of arthritogenic autoimmune response to cartilage proteins. There is therefore not a straightforward explanation for the joint predilection in either model. It has not yet been possible, however, to transfer adjuvant-induced arthritis with serum and, in this case, T cells seem to represent the only critical cell type that contains immune specificity. There are two principally different ways for adjuvants to induce arthritisone is the triggering of innate immunity towards bacterial cell-wall components and the other is the solubilisation in cell membranes of the oil component used in adjuvants. Both of these processes trigger a more or less joint-specific inflammatory response that can develop into a chronic disease course with extensive similarities to rheumatoid arthritis. The chronic disease course is driven by a different set of genes from those controlling the onset of arthritis and may involve other mechanisms such as cartilage-reactive T cells or pathogenic autoantibodies [7] . There is a pronounced activation of the acute-phase Dispatch R529 Table 1 The variety of different arthritic diseases in man and animals. An estimate of the intensity of the pathological process is graded from normal (-), minor changes (+), moderate changes (++), and severe changes (+++). A slash indicates variability in different animals/individuals or observations. *Inflammation of the joint capsule. † Disease process in the insertion area of tendons or ligaments usually leading to the formation of new cartilage and bone.
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Taken together, the various animal models reflect different parts of the pathology seen in rheumatoid arthritis and several of them will be useful for elucidating the different pathways. So, are there any specific events in rheumatoid arthritis on which the new model could shed some light? Despite the phenotypic and genetic heterogeneity of rheumatoid arthritis, there are several phenomena that surprisingly are shared by most rheumatoid arthritis patients.
One commonality is the association of arthritis severity and chronicity with certain MHC class II alleles. Another is the contraction of the T-cell repertoire leading to a few clonotypes that possibly reflects positive selection of Tcell autoreactivity. A third phenomenon is the occurrence of certain autoantibody reactivities in sera. It has recently been demonstrated that autoantibodies preferentially occurring in rheumatoid arthritis are not only specific for immunoglobulin Fc (rheumatoid factors) and type II collagen but also for a series of different more or less welldefined autoantigens such as the A2 protein of the heterogeneous nuclear ribonucleoprotein complex, the SA protein and various citrullinated proteins [8, 9] . Although these reactivities are most likely involved at a secondary level in the disease process, it would be interesting to investigate whether there is a correlation between the reactivities of the presently described pathogenic IgG antibodies and these autoantibodies. In fact, the induction of autoantibodies as a secondary effect may be important not only for sustaining arthritis but also for development of systemic manifestations, such as inflammation of serous membranes (serositis) and blood vessels (vasculitis). The observation that the reported T-cell receptor transgenic mice did not only develop arthritis but also serositis could be of further interest.
At this stage, therefore, the new model has raised more questions than answers and the key factor will be its applicability for further analysis of the pathogenic mechanisms of rheumatoid arthritis. In this respect, this model has some clear advantages. It should be possible to isolate the autoantigenic peptide recognised by the transgenic T cells, as well as the epitope(s) recognised by the pathogenic antibodies. This might be a valuable tool to investigate the link between the apparent recognition of a ubiquitously expressed pathogen and an organ-specific inflammatory attack. The most important contribution might be, however, that the model reveals a new pathway that can be investigated in detail by genetic techniques and can be compared with other pathways used in different models for rheumatoid arthritis. The antibody-mediated induction of arthritis occurs rapidly with high penetrance and is most likely controlled by a specific set of genes that will be both similar to and different from other animal models for rheumatoid arthritis.
